Jacobs Levy Equity Management
SPRB

Jacobs Levy Equity Management’s Spruce Biosciences SPRB Stock Holding History

Jacobs Levy Equity Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-325
Closed -$146K – 1092
2021
Q3 		$146K Buy
+325
New +$204K ﹤0.01% 1004

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management's SPRB Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Spruce Biosciences (SPRB) in Q4 2021, closing a stake of 325 shares — an estimated $146K sold.

Jacobs Levy Equity Management first reported a position in SPRB in Q3 2021 and held it in 1 quarter. The position peaked at $146K in Q3 2021. 50 funds tracked by Wall St. Rank hold SPRB as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Spruce Biosciences position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 325 Spruce Biosciences shares in Q4 2021, an estimated $146K.
  • Jacobs Levy Equity Management first reported a position in Spruce Biosciences in Q3 2021 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Spruce Biosciences position peaked at $146K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.